title: Direct effect of PGF2α pulses on PRL pulses, based on inhibition of PRL or PGF2α secretion in heifers.
abstract: The relationships between PRL and PGF(2α) and their effect on luteolysis were studied. Heifers were treated with a dopamine-receptor agonist (bromocriptine; Bc) and a Cox-1 and -2 inhibitor (flunixin meglumine [FM]) to inhibit PRL and PGF(2α), respectively. The Bc was given (Hour 0) when ongoing luteolysis was indicated by a 12.5% reduction in CL area (cm(2)) from the area on Day 14 postovulation, and FM was given at Hours 0, 4, and 8. Blood samples were collected every 8-h beginning on Day 14 until Hour 48 and hourly for Hours 0 to 12. Three groups of heifers in ongoing luteolysis were used: control (n = 7), Bc (n = 7), and FM (n = 4). Treatment with Bc decreased (P < 0.003) the PRL concentrations averaged over Hours 1 to 12. During the greatest decrease in PRL (Hours 2-6), LH concentrations were increased. Progesterone concentrations averaged over hours were greater (P < 0.05) in the Bc group than in the controls. In the FM group, no PGFM pulses were detected, and PRL concentrations were reduced. Concentrations of PGFM were not reduced in the Bc group, despite the reduction in PRL. Results supported the hypothesis that a decrease (12.5%) in CL area (cm(2)) is more efficient in targeting ongoing luteolysis (63%) than using any day from Days 14 to ≥ 19 (efficiency/day, 10-24%). The hypothesis that PRL has a role in luteolysis was supported but was confounded by the known positive effect of LH on progesterone. The hypothesis was supported that the synchrony of PGFM and PRL pulses represents a positive effect of PGF(2α) on PRL, rather than an effect of PRL on PGF(2α).
authors.affiliation: Eutheria Foundation, Cross Plains, Wisconsin 53528, USA.
authors.forename: F L V
authors.initials: FL
authors.lastname: Pinaffi
authors.forename: G
authors.initials: G
authors.lastname: Pugliesi
authors.forename: M A
authors.initials: MA
authors.lastname: Hannan
authors.forename: L A
authors.initials: LA
authors.lastname: Silva
authors.forename: M A
authors.initials: MA
authors.lastname: Beg
authors.forename: O J
authors.initials: OJ
authors.lastname: Ginther
mesh_terms: D000818:Animals; D001971:Bromocriptine / Q000494:pharmacology; D002417:Cattle / Q000502:physiology*; D003002:Clonixin / Q000031:analogs & derivatives / Q000494:pharmacology; D016861:Cyclooxygenase Inhibitors / Q000494:pharmacology; D015237:Dinoprost / Q000008:administration & dosage* / Q000037:antagonists & inhibitors / Q000097:blood*; D018491:Dopamine Agonists / Q000494:pharmacology; D004347:Drug Interactions; D005260:Female; D007986:Luteinizing Hormone / Q000097:blood; D003341:Luteolysis / Q000187:drug effects; D010507:Periodicity; D011374:Progesterone / Q000097:blood; D011388:Prolactin / Q000008:administration & dosage* / Q000037:antagonists & inhibitors / Q000097:blood*
chemical_list: D016861:Cyclooxygenase Inhibitors; D018491:Dopamine Agonists; D001971:Bromocriptine; D011374:Progesterone; C014558:flunixin meglumine; D011388:Prolactin; D007986:Luteinizing Hormone; D015237:Dinoprost; D003002:Clonixin